secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168973
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney to purchase Greensboro, NC manufacturing facility for $25.5M; eligible for $13.3M tax credits
--------------------------------------------------------------------------------

- Purchase price of ~$25.5M cash for a 210K sq ft facility and 22 acres; expected close by end of June 2023.
- Company eligible for up to $13.3M in tax credits from city, county, and state; requires 330+ new jobs by Dec 2028 and ~$458M investment by Dec 2027.
- Facility will support commercial manufacturing for REACT cell therapy, currently in Phase 3 trials for diabetic CKD.
- Cash as of March 31, 2023 expected to fund operations through interim results from proact 1 trial, anticipated in late 2024.
- Company targeting BLA submission for FDA approval in 2026 with potential U.S. commercial launch later that year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/0001193125-23-168973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/d475847d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer